My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

5.617 +0.127 (+2.32%)
Streaming Delayed Price Updated: 12:46 PM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
Company to host public (L)earnings call on February 28th at 8:30 am ET / 6:30 am MT / 1:30 pm GMT 
From Recursion Pharmaceuticals
Via GlobeNewswire
Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?
Recursion Pharmaceuticals' stock has soared due to Nvidia's continued investment, positioning the company as a leader in AI-driven drug discovery. 
Via MarketBeat
Topics Artificial Intelligence Regulatory Compliance
SoundHound and Serve Robotics Are Dropping Like a Rock -- Why Nvidia Was the Catalyst
Nvidia sold their stake in some high-flying stocks recently. 
Via The Motley Fool
Where Recursion Pharmaceuticals Stands With Analysts
 
Via Benzinga
How Is The Market Feeling About Recursion Pharmaceuticals?
 
Via Benzinga
Is Recursion Pharmaceuticals Stock a Buy?
Via The Motley Fool
Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City
The Altitude Lab Fund aims to deliver strong returns to Limited Partners, accelerate the growth of Salt Lake City’s Life Science hub, and enable high potential startups support while federal funding is... 
From Recursion Pharmaceuticals
Via GlobeNewswire
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
25 Top AI Stocks That Could Boost Your Portfolio
Via The Motley Fool
Topics Artificial Intelligence
Altitude Lab Startups Raise $154M in Capital
The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones 
From Recursion Pharmaceuticals
Via GlobeNewswire
SoftBank Joins Nvidia In Backing Recursion Pharma, Retail Traders Rally Behind Stock Surge
The Japanese conglomerate’s bet comes amid growing AI sector momentum, fueled in part by chipmaking giant Nvidia, which also holds over 7.7 million Recursion shares. 
Via Stocktwits
Topics Artificial Intelligence
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%) 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Why Recursion Pharmaceuticals Stock Is Soaring Today
Via The Motley Fool
Nvidia Invests in These 2 Artificial Intelligence (AI) Stocks and Sells These 3 Others
Nvidia's 13F revealed some interesting choices. 
Via The Motley Fool
Topics Artificial Intelligence
Why SoundHound AI and Serve Robotics Stock Crashed on Friday
Via The Motley Fool
Topics Artificial Intelligence
Nvidia Dumps SoundHound, Trims Arm Stake, Buys These 2 Stocks
Nvidia disclosed in a regulatory filing Friday that it sold off three tech stocks and added stakes in two others. Nvidia stock rose. 
Via Investor's Business Daily
Biotechs on the Brink: 2 Stocks With Huge Potential
BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out. 
Via MarketBeat
Why Coherent Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
3 Monster Stocks to Hold for the Next 10 Years
A handful of companies are in the right place at the right time with the right product or service. 
Via The Motley Fool
AI Pharma: 2 Paths to AI-Powered Drug Investment
AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients. 
Via MarketBeat
Topics Artificial Intelligence
Nvidia-Backed Recursion Pharma Hits 3-Week High, Sparks Retail Buzz Amid Broader AI Hype
The AI chipmaker’s $50 million investment in Recursion, unveiled in 2023 to support AI-driven drug discovery, has been a key driver of investor interest. 
Via Stocktwits
Topics Artificial Intelligence
Seagate Posts Upbeat Earnings, Joins Netflix, Travelers, Teledyne Technologies And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025
Via The Motley Fool
AI Drug Discovery Startups: Analysis Of Exscientia’s Acquisition By Recursion
Exscientia is a European player looking to make a difference in the AI-drug discovery market. Like other players, it has an interesting story to tell. After a brief listing on the stock market,... 
Via Talk Markets
Topics Artificial Intelligence Stocks / Equities
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce
Ark Invest, led by Cathie Wood, made significant trades in 5 companies on Friday: RXRX, ILMN, NTLA, NET, and ADPT. 
Via Benzinga
Topics Workforce
AI Drug Discovery Stocks: Recursion Pharmaceuticals Has A Long Road Ahead
Among the various use-cases for AI, healthcare has been one of the interesting ones. Recursion Pharmaceuticals (RXRX) is one such notable player in the industry that has successfully leveraged AI in... 
Via Talk Markets
Topics Artificial Intelligence Stocks / Equities
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.